Janux Therapeutics (JANX) Current Assets (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.0 billion, down 2.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 2.08% YoY), and the FY2025 annual result was $975.9 million, down 5.59% from the prior year.
• Current Assets grew to $1.0 billion in Q1 2026 per JANX's latest filing, from $975.9 million in the prior quarter.
• Over five years, Current Assets peaked at $1.0 billion in Q4 2024 and troughed at $309.3 million in Q2 2023.
• A 5-year average of $632.9 million and a median of $658.7 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets fell 13.62% in 2023, then jumped 195.97% in 2024.
• A 5-year view of Current Assets shows it stood at $332.4 million in 2022, then rose by 5.05% to $349.2 million in 2023, then jumped by 195.97% to $1.0 billion in 2024, then declined by 5.59% to $975.9 million in 2025, then climbed by 2.68% to $1.0 billion in 2026.
• Business Quant data shows JANX's Current Assets at $1.0 billion in Q1 2026, $975.9 million in Q4 2025, and $998.1 million in Q3 2025.